ASSOCIATION BETWEEN SERUM CARBOXYMETHYL‐LYSINE, A DOMINANT ADVANCED GLYCATION END PRODUCT, AND ANEMIA IN ADULTS: THE BALTIMORE LONGITUDINAL STUDY OF AGING

To the Editor: The pathophysiology of anemia in older adults is incompletely understood, and a substantial proportion of anemia in this population remains unexplained.1 The factors that play a role in anemia in adults are incompletely identified. Advanced glycation end products (AGEs) are a heterogeneous group of bioactive molecules formed by the nonenzymatic glycation of proteins, lipids, and nucleic acids.2 AGEs have been widely implicated in the pathogenesis of cardiovascular and renal disease, and diabetes.2,3

[1]  G. Striker,et al.  Glycotoxins in the diet promote diabetes and diabetic complications , 2007, Current diabetes reports.

[2]  K. Dhatariya,et al.  Trends in bed occupancy for inpatients with diabetes before and after the introduction of a diabetes inpatient specialist nurse service , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[3]  Luigi Ferrucci,et al.  Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. , 2004, Blood.

[4]  Merlin C. Thomas,et al.  Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. , 2004, Kidney international.

[5]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[6]  H. Ukeda,et al.  Effect of carbonyl compounds on red blood cells deformability. , 2004, Biochemical and biophysical research communications.

[7]  Irl B Hirsch,et al.  Management of diabetes and hyperglycemia in hospitals. , 2004, Diabetes care.

[8]  S. Dixon,et al.  Evaluation of a hospital diabetes specialist nursing service: a randomized controlled trial , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[9]  P. Donnan,et al.  Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. , 2000, Diabetes care.

[10]  S. Horiuchi,et al.  Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. , 1999, Biochemical and biophysical research communications.

[11]  I. Maruyama,et al.  N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. , 1998, Kidney international.

[12]  L. Poretsky,et al.  Effects of an Intervention by a Diabetes Team in Hospitalized Patients With Diabetes , 1997, Diabetes Care.

[13]  J. Peters,et al.  Patterns of In and Out‐patient Activity for Diabetes: a District Survey , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[14]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[15]  C. Levetan,et al.  Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. , 1995, The American journal of medicine.

[16]  A. Schmidt,et al.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Ellie Feddersen,et al.  An Inpatient Diabetes Educator's Impact on Length of Hospital Stay , 1994, The Diabetes educator.

[18]  I. Rossman,et al.  Normal Human Aging: The Baltimore Longitudinal Study of Aging , 1986 .

[19]  David Arenberg,et al.  Normal Human Aging: The Baltimore Longitudinal Study on Aging , 1984 .